ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

1:00PM-3:00PM: Abstract Number: 1950

Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 2011

More Meticulously Following Treat-to-target in RA Does Not Lead to Less Radiographic Progression: A Longitudinal Analysis in BIODAM

RA – Treatment Poster IV

1:00PM-3:00PM: Abstract Number: 1775

More Than Half of Patients with Osteoarthritis Have Positive Screening for Fibromyalgia And/or Depression, Feasibly Assessed in Routine Care on Indices Within a Single MDHAQ (multidimensional Health Assessment Questionnaire)

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1778

More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic

Epidemiology and Public Health Poster III

1:00PM-3:00PM: Abstract Number: 1953

Mortality in Rheumatoid Arthritis: Changing Causes and Predictive Factors. Study of a Cohort Followed Prospectively

RA – Diagnosis, Manifestations, and Outcomes Poster IV

1:00PM-3:00PM: Abstract Number: 1845

Mortality Prognostic Factors of Critically Ill Patients with Systemic Autoimmune Diseases Admitted in a Medical Intensive Care Unit: A 20-year Cohort Study

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1922

Multi-Joint Osteoarthritis Phenotypes by Race/Ethnicity and Sex: Preliminary Descriptive Data from the Johnston County Health Study

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1741

Mutated Nod2 Controls T Cell Function and Promotes Uveitis in a Blau Syndrome Mouse Model

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 1877

Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies

Muscle Biology, Myositis and Myopathies Poster II

1:00PM-3:00PM: Abstract Number: 2025

Natural History of Sjögren’s Disease from the National Institutes of Health Cohort

Sjögren's Syndrome – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1918

Neurobiological Mechanisms of a Remote-Delivered Mind-body Intervention for Knee Osteoarthritis

Osteoarthritis – Clinical Poster

1:00PM-3:00PM: Abstract Number: 1803

Neutrophil-to-lymphocyte Ratio Among Flaring and Non-flaring Uncontrolled Gout Patients Undergoing Pegloticase Therapy as Part of the Phase 3 Pivotal Trials

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1854

Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions

Miscellaneous Rheumatic and Inflammatory Diseases Poster III

1:00PM-3:00PM: Abstract Number: 1719

NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model

SLE – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 1931

NOD2 Mutations Are Associated with Upregulated Type 1 Interferon Gene Expression and Development of Granulomatous Hepatitis in Children with Autoimmune Hepatitis

Pediatric Rheumatology – Clinical Poster III: Other

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].